Literature DB >> 26375298

Fluorescence Based Characterization of Calcium Sensitizer Action on the Troponin Complex.

William Schlecht1, King-Lun Li1, Dehong Hu2, Wenji Dong1.   

Abstract

Calcium sensitizers enhance the transduction of the Ca(2+) signal into force within the heart and have found use in treating heart failure. However the mechanisms of action for most Ca(2+) sensitizers remain unclear. To address this issue an efficient fluorescence based approach to Ca(2+) sensitizer screening was developed which monitors cardiac troponin C's (cTnC's) hydrophobic cleft. This approach was tested on four common Ca(2+) -sensitizers, EMD 57033, levosimendan, bepridil and pimobendan with the aim of elucidating the mechanisms of action for each as well as proving the efficacy of the new screening method. Ca(2+) -titration experiments were employed to determine the effect on Ca(2+) sensitivity and cooperativity of cTnC opening, while stopped flow experiments were used to investigate the impact on cTnC relaxation kinetics. Bepridil was shown to increase the sensitivity of cTnC for Ca(2+) under all reconstitution conditions, sensitization by the other drugs was context dependent. Levosimendan and pimobendan reduced the rate of cTnC closing consistent with a stabilization of cTnC's open conformation while bepridil increased the rate of relaxation. Experiments were also run on samples containing cTnT(T204E), a known Ca(2+) -desensitizing phosphorylation mimic. Levosimendan, bepridil, and pimobendan were found to elevate the Ca(2+) -sensitivity of cTnT(T204E) containing samples in this context.
© 2015 John Wiley & Sons A/S.

Entities:  

Keywords:  cardiac tropnin; drug screening; fluorescence spectroscopy

Mesh:

Substances:

Year:  2015        PMID: 26375298      PMCID: PMC4718833          DOI: 10.1111/cbdd.12651

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  53 in total

1.  Interaction of bepridil with the cardiac troponin C/troponin I complex.

Authors:  E Abusamhadneh; M B Abbott; A Dvoretsky; N Finley; S Sasi; P R Rosevear
Journal:  FEBS Lett       Date:  2001-09-28       Impact factor: 4.124

2.  Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033.

Authors:  X Wang; M X Li; L Spyracopoulos; N Beier; M Chandra; R J Solaro; B D Sykes
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

3.  Ca(2+) induces an extended conformation of the inhibitory region of troponin I in cardiac muscle troponin.

Authors:  W J Dong; J Xing; J M Robinson; H C Cheung
Journal:  J Mol Biol       Date:  2001-11-16       Impact factor: 5.469

4.  Preparation and identification of alpha- and beta-tropomyosins.

Authors:  L B Smillie
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

5.  Bepridil opens the regulatory N-terminal lobe of cardiac troponin C.

Authors:  Y Li; M L Love; J A Putkey; C Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

Authors:  T Sorsa; S Heikkinen; M B Abbott; E Abusamhadneh; T Laakso; C Tilgmann; R Serimaa; A Annila; P R Rosevear; T Drakenberg; P Pollesello; I Kilpelainen
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

7.  Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium.

Authors:  R Takahashi; M A Talukder; M Endoh
Journal:  Eur J Pharmacol       Date:  2000-07-14       Impact factor: 4.432

8.  Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone.

Authors:  K Fujino; N Sperelakis; R J Solaro
Journal:  Circ Res       Date:  1988-11       Impact factor: 17.367

9.  Different effect of the Ca(2+) sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium.

Authors:  K Brixius; U Mehlhorn; W Bloch; R H Schwinger
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

10.  Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study.

Authors:  L K MacLachlan; D G Reid; R C Mitchell; C J Salter; S J Smith
Journal:  J Biol Chem       Date:  1990-06-15       Impact factor: 5.157

View more
  7 in total

1.  Dynamic Equilibrium of Cardiac Troponin C's Hydrophobic Cleft and Its Modulation by Ca2+ Sensitizers and a Ca2+ Sensitivity Blunting Phosphomimic, cTnT(T204E).

Authors:  William Schlecht; Wen-Ji Dong
Journal:  Bioconjug Chem       Date:  2017-09-18       Impact factor: 4.774

2.  Changes in the dynamics of the cardiac troponin C molecule explain the effects of Ca2+-sensitizing mutations.

Authors:  Charles M Stevens; Kaveh Rayani; Gurpreet Singh; Bairam Lotfalisalmasi; D Peter Tieleman; Glen F Tibbits
Journal:  J Biol Chem       Date:  2017-05-22       Impact factor: 5.157

3.  Sarcomere integrated biosensor detects myofilament-activating ligands in real time during twitch contractions in live cardiac muscle.

Authors:  Anthony D Vetter; Ashley A Martin; Brian R Thompson; David D Thomas; Joseph M Metzger
Journal:  J Mol Cell Cardiol       Date:  2020-08-11       Impact factor: 5.000

4.  Treatments targeting inotropy.

Authors:  Christoph Maack; Thomas Eschenhagen; Nazha Hamdani; Frank R Heinzel; Alexander R Lyon; Dietmar J Manstein; Joseph Metzger; Zoltán Papp; Carlo G Tocchetti; M Birhan Yilmaz; Stefan D Anker; Jean-Luc Balligand; Johann Bauersachs; Dirk Brutsaert; Lucie Carrier; Stefan Chlopicki; John G Cleland; Rudolf A de Boer; Alexander Dietl; Rodolphe Fischmeister; Veli-Pekka Harjola; Stephane Heymans; Denise Hilfiker-Kleiner; Johannes Holzmeister; Gilles de Keulenaer; Giuseppe Limongelli; Wolfgang A Linke; Lars H Lund; Josep Masip; Marco Metra; Christian Mueller; Burkert Pieske; Piotr Ponikowski; Arsen Ristić; Frank Ruschitzka; Petar M Seferović; Hadi Skouri; Wolfram H Zimmermann; Alexandre Mebazaa
Journal:  Eur Heart J       Date:  2019-11-21       Impact factor: 29.983

5.  Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.

Authors:  Xiao-Ran Cui; Xiao-Hong Yang; Rui-Bin Li; Dong Wang; Min Jia; Long Bai; Ji-Dong Zhang
Journal:  Cardiovasc J Afr       Date:  2020-06-12       Impact factor: 1.167

6.  Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog.

Authors:  Sandra E Pineda-Sanabria; Ian M Robertson; Yin-Biao Sun; Malcolm Irving; Brian D Sykes
Journal:  J Mol Cell Cardiol       Date:  2016-02-04       Impact factor: 5.000

Review 7.  Sarcomere Dysfunction in Nemaline Myopathy.

Authors:  Josine M de Winter; Coen A C Ottenheijm
Journal:  J Neuromuscul Dis       Date:  2017
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.